FI113965B - 8-okso-4-oksa-1,7-diatsatrisyklo-oktadekatetraen-9-yylikarbamoyylijohdannaiset matriisimetalloproteaasi-inhibiittoreina - Google Patents

8-okso-4-oksa-1,7-diatsatrisyklo-oktadekatetraen-9-yylikarbamoyylijohdannaiset matriisimetalloproteaasi-inhibiittoreina Download PDF

Info

Publication number
FI113965B
FI113965B FI973198A FI973198A FI113965B FI 113965 B FI113965 B FI 113965B FI 973198 A FI973198 A FI 973198A FI 973198 A FI973198 A FI 973198A FI 113965 B FI113965 B FI 113965B
Authority
FI
Finland
Prior art keywords
oxa
oxo
tricyclo
diaza
octadeca
Prior art date
Application number
FI973198A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI973198L (fi
FI973198A0 (fi
Inventor
Arlindo L Castelhano
Stephen Horne
Teng J Liak
Paul D Cannon
Jian Jeffrey Chen
Alexander Krantz
Wart Harold Van
Zhengyo Yuan
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of FI973198L publication Critical patent/FI973198L/fi
Publication of FI973198A0 publication Critical patent/FI973198A0/fi
Application granted granted Critical
Publication of FI113965B publication Critical patent/FI113965B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI973198A 1995-02-03 1997-08-01 8-okso-4-oksa-1,7-diatsatrisyklo-oktadekatetraen-9-yylikarbamoyylijohdannaiset matriisimetalloproteaasi-inhibiittoreina FI113965B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38281895 1995-02-03
US08/382,818 US6013792A (en) 1993-08-05 1995-02-03 Matrix metalloprotease inhibitors
US9601506 1996-02-02
PCT/US1996/001506 WO1996023791A1 (en) 1995-02-03 1996-02-02 Bridged indoles as matrix metalloprotease inhibitors

Publications (3)

Publication Number Publication Date
FI973198L FI973198L (fi) 1997-08-01
FI973198A0 FI973198A0 (fi) 1997-08-01
FI113965B true FI113965B (fi) 2004-07-15

Family

ID=23510527

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973198A FI113965B (fi) 1995-02-03 1997-08-01 8-okso-4-oksa-1,7-diatsatrisyklo-oktadekatetraen-9-yylikarbamoyylijohdannaiset matriisimetalloproteaasi-inhibiittoreina

Country Status (18)

Country Link
US (1) US6013792A (cs)
EP (1) EP0807114A1 (cs)
JP (1) JPH11500109A (cs)
KR (1) KR100403687B1 (cs)
CN (1) CN1066150C (cs)
AR (1) AR002958A1 (cs)
AU (1) AU705763B2 (cs)
BR (1) BR9606998A (cs)
CA (1) CA2212236A1 (cs)
CZ (1) CZ293868B6 (cs)
FI (1) FI113965B (cs)
HU (1) HUP9702073A3 (cs)
NO (1) NO311257B1 (cs)
PL (1) PL321659A1 (cs)
RU (1) RU2191779C2 (cs)
UA (1) UA67716C2 (cs)
WO (1) WO1996023791A1 (cs)
ZA (1) ZA96850B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990072009A (ko) * 1995-08-12 1999-09-27 게리 이. 프리드만 메탈로프로티나제 방해제, 그를 포함하는 약제 조성물 및 약제로서의 용도, 그리고 그의 제조방법 및 제조에 유용한 중간체
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
GB9715030D0 (en) * 1997-07-18 1997-09-24 British Biotech Pharm Metalloproteinase inhibitors
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9907055D0 (en) 1999-03-29 1999-05-19 British Biotech Pharm Antibacterial agents
UY27192A1 (es) * 2001-03-01 2002-09-30 Smithkline Beecham Corp Inhibidores de peptido-deformilasa
UY27813A1 (es) * 2002-05-31 2003-12-31 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
US20040192658A1 (en) * 2002-12-27 2004-09-30 Angiotech International Ag Compositions and methods of using collajolie
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2526907C (en) * 2003-01-17 2012-11-13 Advanced Proteome Therapeutics, Inc. Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
AU2003902115A0 (en) * 2003-05-02 2003-05-22 The University Of Queensland Method of predicting functional outcome of a stroke using eeg measures
RU2247563C1 (ru) * 2003-06-16 2005-03-10 Пятигорская государственная фармацевтическая академия Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
WO2005012332A1 (en) * 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
RU2257386C1 (ru) * 2004-05-05 2005-07-27 Пермский государственный университет 20-ароил-12-гидрокси-17,17-диметил-3-фенил-3,10,13- триазапентацикло[10.7.1.01,10.04,9.014,19]эйкоза-4,6,8,14(19)-тетраен- 2,11,15- трионы и способ их получения
KR100753796B1 (ko) 2006-07-28 2007-08-31 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물
UA108596C2 (xx) * 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
CN105801530A (zh) * 2016-04-13 2016-07-27 成都拿盛科技有限公司 一种4位取代的手性γ-丁内酯的合成方法
KR20220105061A (ko) 2021-01-19 2022-07-26 (주)월드트렌드 밀착력과 착용감 향상 및 수시 교체가 가능한 안경테와 코 받침의 조립구조

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
EP0586537A4 (en) * 1991-05-28 1997-06-25 Merck & Co Inc Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
GB9122859D0 (en) * 1991-10-28 1991-12-11 Smithkline Beecham Plc Novel compounds
RU2112515C1 (ru) * 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза
CA2168791A1 (en) * 1993-08-05 1995-02-16 Arlindo L. Castelhano Matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
FI973198L (fi) 1997-08-01
AR002958A1 (es) 1998-05-27
WO1996023791A1 (en) 1996-08-08
CZ293868B6 (cs) 2004-08-18
UA67716C2 (en) 2004-07-15
HUP9702073A3 (en) 1999-05-28
RU2191779C2 (ru) 2002-10-27
CZ243197A3 (cs) 1998-01-14
AU705763B2 (en) 1999-06-03
CN1066150C (zh) 2001-05-23
BR9606998A (pt) 1997-10-28
HUP9702073A2 (hu) 1998-03-30
US6013792A (en) 2000-01-11
NO311257B1 (no) 2001-11-05
CN1180358A (zh) 1998-04-29
CA2212236A1 (en) 1996-08-08
AU4863696A (en) 1996-08-21
PL321659A1 (en) 1997-12-22
NO973551D0 (no) 1997-08-01
NO973551L (no) 1997-10-03
ZA96850B (en) 1997-11-03
KR100403687B1 (ko) 2004-02-11
FI973198A0 (fi) 1997-08-01
EP0807114A1 (en) 1997-11-19
JPH11500109A (ja) 1999-01-06

Similar Documents

Publication Publication Date Title
FI113965B (fi) 8-okso-4-oksa-1,7-diatsatrisyklo-oktadekatetraen-9-yylikarbamoyylijohdannaiset matriisimetalloproteaasi-inhibiittoreina
RU2163232C2 (ru) Карбоксамиды, способ их получения и фармацевтическая композиция
EP0721944B1 (en) Imidazolidine derivative and use thereof
US6218389B1 (en) Acyclic metalloprotease inhibitors
RU2132327C1 (ru) Замещенные карбоксамиды и фармацевтическая композиция на их основе
WO1993013066A1 (en) Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
KR100347646B1 (ko) 매트릭스메탈로프로테아제억제제
SK25799A3 (en) Heterocyclic metalloprotease inhibitors
KR19990036271A (ko) 콜라겐 과다생산과 연관된 질환의 치료에 이용되는 c-프로테나제 저해물질
KR20000035917A (ko) 1,4-헤테로고리성 메탈로프로테아제 저해제
CS621585A2 (en) Method of analynprolinone derivatives production
CA2886526C (en) (4-cyclopropyl-2,5-dioxo-imidazolidin-4-yl)methyl amide compounds and their use as aggrecanase inhibitors
EA002746B1 (ru) Стимуляторы секреции гормона роста
JP4384277B2 (ja) 置換された6−および7−アミノテトラヒドロイソキノリンカルボン酸
EP1115390B1 (en) Hydroxamate-containing cysteine and serine protease inhibitors
US5773428A (en) Matrix metalloprotease inhibitors
TW203008B (cs)

Legal Events

Date Code Title Description
MA Patent expired